What It Is
Mechano growth factor (MGF) is a name used in muscle-biology research for a splice variant of insulin-like growth factor 1 (IGF-1) — a different way the IGF1 gene's product is processed when skeletal muscle experiences mechanical load or damage during exercise or injury.[1] In practice, "MGF peptide" as sold online usually means a synthetic fragment modeled on the E-domain portion of this variant, not the natural process itself.
MGF is not an approved drug. No FDA-reviewed label, indication, or standardized dose exists for it; it is sold exclusively as a research chemical, with vendor pages stating it is not intended for human or animal consumption.[2]
How It Works
The working hypothesis is that mechanical stress and local tissue damage change how the IGF1 gene is spliced in muscle, temporarily increasing this E-domain-containing variant right after exercise or injury.[3] Preclinical work links its expression to activation of satellite cells — the muscle's resident stem cells — and to early proliferation of the myoblasts that repair damaged fibers, ahead of the later-stage work done by mature IGF-1.
Cell studies suggest the short E-domain peptide behaves differently from mature IGF-1 in myoblast experiments, but the specific receptor and signaling pathway it uses are far less established than the well-characterized IGF-1 receptor pathway.[4]
What the Research Shows
Human evidence on MGF is essentially limited to gene-expression studies: researchers have measured IGF-1 splice-variant activity in muscle biopsies after resistance exercise in young and older adults.[5] That helps explain how muscle responds to training, but it says nothing about whether a synthetic MGF peptide has any effect — no registered human trial of MGF peptide therapy was found in a ClinicalTrials.gov search.
The rest of the evidence is preclinical: rodent studies linking MGF expression to satellite-cell activation after induced muscle injury, cell-culture work showing a synthetic E-domain peptide affecting myoblast proliferation, and limited cardiac cell-model experiments.[6] None of this shows that an administered MGF peptide builds muscle, speeds recovery, or is safe for human use.
Safety & Side Effects
Because no approved label or human trial exists, there is no regulator-reviewed accounting of MGF's side effects. The available information is a mix of gaps and theoretical concerns rather than reassurance:
- Anecdotal online reports of injection-site irritation or fatigue, none of which establish incidence or a causal link
- Unresolved theoretical concerns tied to growth-factor and IGF-1 signaling, relevant to anyone with a history of cancer, proliferative disorders, or complex endocrine conditions
- No data on pregnancy, breastfeeding, or long-term use
- Generic contamination, mislabeling, and purity risks common to compounded or unapproved research peptides
Regulatory Status
MGF has no FDA-approved therapeutic indication and no equivalent approval identified in any other regulatory database reviewed; it exists only as a "research use only" product.[7] The World Anti-Doping Agency lists mechano growth factors among prohibited growth-factor substances, so it is treated as banned in tested sport even though it isn't approved as a medicine anywhere.
PEG-MGF and Product Variants
A related product, PEG-MGF, attaches polyethylene glycol to the peptide — a modification used elsewhere in drug development to extend circulation time and change clearance.[8] That general PEGylation science does not transfer automatically to MGF: no clinical pharmacokinetic or safety data exist for PEG-MGF specifically, and modifying a peptide can introduce its own immune-response or quality concerns rather than simply making it "longer-acting."
Native (endogenous) MGF, synthetic E-domain research peptides, and PEG-MGF are three distinct things. A study of gene expression after exercise does not validate a synthetic product, and a cell experiment does not establish a dose for a chemically modified one — treating them as interchangeable is a common but misleading shortcut.